High expression of HLA-DQA1 predicts poor outcome in patients with esophageal squamous cell carcinoma in Northern China

Background: Our previous studies demonstrate that the major histocompatibility complex (MHC) is associated with the progression of esophageal squamous cell carcinoma (ESCC). HLA-DQA1, which belongs to the MHC Class II family, may be a potential biomarker in ESCC progression. However, the association between HLA-DQA1 and ESCC in high-incidence area of northern China has not been well characterized. The purpose of this study is to investigate the relationship of HLA-DQA1 expression with the progression and prognosis of ESCC. Methods: We analyzed the expression profiles of HLA-DQA1 in esophageal cancer (EC) samples in the TCGA database and validated HLA-DQA1 expression by immunohistochemistry, western blotting, and quantitative reverse-transcription polymerase chain reaction in matched EC and normal tissues, respectively. The correlation between HLA-DQA1 expression and clinicopathologic characteristics of ESCC was further analyzed. Result: Immunohistochemical analysis indicated that the expression level of HLA-DQA1 in ESCC tissues was significantly higher than the matched normal tissues (P < .001). HLA-DQA1 mRNA and protein expression were significantly higher in ESCC tissues compared to the matched normal tissues. Patients with family history negative or with tumor sizes >4 cm were associated with higher HLA-DQA1 expression levels. A prognostic significance of HLA-DQA1 was also found by the Log-rank method, in which high expression of HLA-DQA1 was correlated with a shorter overall survival time. The receiver operating characteristic (ROC) curve analysis yielded the area under the ROC curve value of 0.693. Univariate and multivariate analyses also suggest that high expression of HLA-DQA1 is a potential indicator for poor prognosis of ESCC. Conclusions: Our results demonstrate that HLA-DQA1 plays an important role in ESCC progression and may be a biomarker for ESCC diagnosis and prognosis, as well as a potential target for the treatment of patients with ESCC.

[1]  F. Zhou,et al.  Variations in the MHC Region Confer Risk to Esophageal Squamous Cell Carcinoma on the Subjects from High-Incidence Area in Northern China , 2014, PloS one.

[2]  P. Su,et al.  Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: Association with disease progression , 2009, Scandinavian journal of gastroenterology.

[3]  Yuzhang Jiang,et al.  Identification of a novel fusion gene (HLA-E and HLA-B) by RNA-seq analysis in esophageal squamous cell carcinoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[4]  A. Epstein,et al.  MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro , 2014, Clinical Cancer Research.

[5]  Hongbing Shen,et al.  Joint analysis of three genome- wide association studies of esophageal squamous cell carcinoma in Chinese populations , 2014 .

[6]  C. Mackall,et al.  Going back to class I: MHC and immunotherapies for childhood cancer , 2015, Pediatric blood & cancer.

[7]  Rong Li,et al.  Overexpressed PTOV1 associates with tumorigenesis and progression of esophageal squamous cell carcinoma , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[8]  J. Bergman,et al.  Survival After Recurrent Esophageal Carcinoma Has Not Improved Over the Past 18 Years , 2013, Annals of Surgical Oncology.

[9]  Chung S. Yang,et al.  Etiology and Prevention of Esophageal Cancer , 2016, Gastrointestinal Tumors.

[10]  M. Shah,et al.  Oesophageal cancer , 2017, Nature Reviews Disease Primers.

[11]  Jesper Lagergren,et al.  Oesophageal cancer , 2017, The Lancet.

[12]  Fan Wang,et al.  PITX2: A promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma , 2012, International journal of cancer.

[13]  Yutaka Suzuki,et al.  Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence , 2016, Oncotarget.

[14]  Xiao-Hui Zheng,et al.  HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF‐1 expression and activates Wnt pathway , 2013, Cancer science.

[15]  J. Li,et al.  Atlas of cancer mortality in the People's Republic of China. An aid for cancer control and research. , 1981, International journal of epidemiology.

[16]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[17]  Xiao-bin Cui,et al.  HLA-DRB1 and HLA-DQB1 methylation changes promote the occurrence and progression of Kazakh ESCC , 2014, Epigenetics.

[18]  S. Qiu,et al.  Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. , 1993, Cancer research.

[19]  M. Abbaszadegan,et al.  Association of PYGO2 and EGFR in esophageal squamous cell carcinoma , 2013, Medical Oncology.

[20]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[21]  F. Novelli,et al.  Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response , 2014, Pancreas.

[22]  Yan Li,et al.  Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma. , 2011, Cancer research.

[23]  Ed Schuuring,et al.  Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma , 2003, Immunogenetics.

[24]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[25]  M. Morita,et al.  Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention , 2010, International Journal of Clinical Oncology.

[26]  K. Chan,et al.  CD68 and interleukin 13, prospective immune markers for esophageal squamous cell carcinoma prognosis prediction , 2016, Oncotarget.

[27]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[28]  G. Yang,et al.  DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. , 2001, Carcinogenesis.

[29]  N. Hu,et al.  GWAS follow-up study of esophageal squamous cell carcinoma identifies potential genetic loci associated with family history of upper gastrointestinal cancer , 2017, Scientific Reports.

[30]  P. Zhang,et al.  Novel genetic locus at MHC region for esophageal squamous cell carcinoma in Chinese populations , 2017, PloS one.

[31]  闵先军,et al.  Oesophageal cancer , 2011 .

[32]  A. Benammar Elgaaied,et al.  CD99 and HLA-II Immunostaining in Breast Cancer Tissue and Their Correlation with Lymph Node Metastasis , 2013, Disease markers.

[33]  T. Zeng,et al.  Downregulation of RBMS 3 Is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma , 2011 .

[34]  Ronald N. Germain,et al.  MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation , 1994, Cell.